Baveno VIII – Advancing consensus in portal hypertension
Year: 2026
Type: article
Abstract: Since the first Baveno Consensus Conference in 1990, successive conferences held every 5 years have transformed the field of cirrhosis and portal hypertension, evolving from a focus on variceal bleeding to a pathophysiology-based framework centred on risk stratification, clinically significant portal hypertension (CSPH), and the prevention of decompensation. Building on this progress, the Baveno Cooperation, in collaboration with the Vascular Liver Disease Interest Group (VALDIG), convened an expert faculty to review the evidence published since Baveno VII and update clinical guidance for patients with advanced chronic liver disease (ACLD), portal hypertension, and vascular liver diseases. The Baveno VIII Consensus Conference, held in March 2026 in Baveno, Italy, was based on a structured consensus process across nine panels addressing key domains of ACLD, portal hypertension, and vascular liver diseases. Statements and recommendations were developed through iterative review of the evidence and voting among faculty, with strong consensus defined as >80% faculty agreement. A total of 272 statements and recommendations achieved strong consensus. Key areas included non-invasive risk stratification in compensated ACLD (cACLD), modifiers of steatotic liver disease, prevention of first and further decompensation, management of portal hypertensive bleeding and further decompensation, cirrhosis recompensation, and vascular liver diseases, including Budd-Chiari syndrome, portosinusoidal vascular disorder (PSVD) or non-cirrhotic portal fibrosis (NCPF), and portal vein thrombosis (PVT). The central role of CSPH and the expanding use of non-invasive tests were reaffirmed, and several diagnostic and prognostic cut-offs were revised. New to Baveno VIII is the inclusion of selected guidance for paediatric patients. Recommendations from previous conferences that were not specifically revised in Baveno VIII, such as those on hepatic venous pressure gradient (HVPG) measurement, remain valid. Finally, a research agenda identifying 153 priority topics is proposed.
Source: Journal of Hepatology
Authors: Annalisa BERZIGOTTI, Mattias MANDORFER, Monica PONS, Juan G. ABRALDES, Elton DAJTI, Joan GENESCA, Mathias JACHS, Tassos GRAMMATIKOPOULOS, Emmanuel A. TSOCHATZIS, Sven MA. FRANCQUE, Laurent CASTERA, Alina M. ALLEN, Alexandre LOUVET, Vincent Wai-Sun WONG, Cristina RIPOLL, Jaume BOSCH, Rafael BANARES, Dhiraj TRIPATHI, Vincenza CALVARUSO, Càndid VILLANUEVA, Jose Ignacio FORTEA, Vishal C. PATEL, Susana G. RODRIGUES, Vincenzo La MURA, Christophe BUREAU, Anahita RABIEE, Gennaro D’AMICO, Puneeta TANDON, Laura TURCO, Manon ALLAIRE, Florent ARTRU, Jonel TREBICKA, Alexander ZIPPRICH, Marika RUDLER, Juan Carlos GARCIA-PAGAN, Wim LALEMAN, Bogdan PROCOPET, Charlotte BOUZBIB, Brett E. FORTUNE, Ron C. GABA, Anna BAIGES, Filippo SCHEPIS, Xuefeng LUO, Ian M. GRALNEK, Dominique THABUT, Salvatore PIANO, Paolo CARACENI, Benjamin MAASOUMY, Agustín ALBILLOS, Dominik BETTINGER, Francesco VIZZUTTI, Jasmohan S. BAJAJ, Helene LARRUE, Rakhi MAIWALL, Guadalupe GARCIA-TSAO, Thomas REIBERGER, Jidong JIA, Douglas A. SIMONETTO, Georg SEMMLER, Elisa POSE, Marta TONON, Terry Cheuk-Fung YIP, Virginia HERNANDEZ-GEA, Dominique-Charles VALLA, Pierre-Emmanuel RAUTOU, Andrea De GOTTARDI, Sarwa DARWISH MURAD, Akash SHUKLA, Katharina LAMPICHLER, Michael PRAKTIKNJO, Christine SEMPOUX, Marco SENZOLO, Laure ELKRIEF, Luis TELLEZ, Maxime RONOT, Aurelie PLESSIER, Sarah SHALABY, Nicolas INTAGLIATA, Paolo SIMIONI, Angelo Di GIORGIO, Shiv Kumar SARIN, Aleksander KRAG, Benjamin SHNEIDER, Jordi GRACIA-SANCHO, Roberto De FRANCHIS
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,500
OpenAlex ID: W7203790801